{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:09:30Z","timestamp":1793736570778,"version":"4.6.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032400","name":"University of Lincoln","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03042-7","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:24:55Z","timestamp":1770881095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes"],"prefix":"10.1186","volume":"25","author":[{"given":"Chelsy L.","family":"Cliff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad U.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna K.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Inghels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"3042_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117607","author":"J Bor\u00e9n","year":"2024","unstructured":"Bor\u00e9n J, \u00d6\u00f6rni K, Catapano AL. The link between diabetes and cardiovascular disease. Atherosclerosis. 2024. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117607.","journal-title":"Atherosclerosis"},{"key":"3042_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2023.04.052","volume":"82","author":"J Morales","year":"2023","unstructured":"Morales J, Handelsman Y. Cardiovascular outcomes in patients with diabetes and kidney disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82:161\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"3042_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12933-024-02479-6","volume":"23","author":"AM Kerola","year":"2024","unstructured":"Kerola AM, Juonala M, Kyt\u00f6 V. Short- and long-term mortality in patients with type 2 diabetes after myocardial infarction\u2014a nationwide registry study. Cardiovasc Diabetol. 2024;23:390.","journal-title":"Cardiovasc Diabetol"},{"key":"3042_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1001\/archinte.164.13.1422","volume":"164","author":"T Almdal","year":"2004","unstructured":"Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422\u20136.","journal-title":"Arch Intern Med"},{"key":"3042_CR5","doi-asserted-by":"publisher","first-page":"e019270","DOI":"10.1161\/JAHA.120.019270","volume":"10","author":"R Nair","year":"2021","unstructured":"Nair R, Johnson M, Kravitz K, Huded C, Rajeswaran J, Anabila M, et al. Characteristics and outcomes of early recurrent myocardial infarction after acute myocardial infarction. J Am Heart Assoc. 2021;10:e019270.","journal-title":"J Am Heart Assoc"},{"key":"3042_CR6","doi-asserted-by":"crossref","unstructured":"Muroke V, Tardif J-C. Inflammation mediates residual cardiovascular risk in statin-treated patients with coronary disease. Eur J Prev Cardiol. 2025;:zwaf258.","DOI":"10.1093\/eurjpc\/zwaf258"},{"key":"3042_CR7","doi-asserted-by":"publisher","first-page":"107238","DOI":"10.1016\/j.vph.2023.107238","volume":"153","author":"PM Ridker","year":"2023","unstructured":"Ridker PM. Targeting residual inflammatory risk: the next frontier for atherosclerosis treatment and prevention. Vascul Pharmacol. 2023;153:107238.","journal-title":"Vascul Pharmacol"},{"key":"3042_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","volume":"45","author":"MA Matter","year":"2024","unstructured":"Matter MA, Paneni F, Libby P, Frantz S, St\u00e4hli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024;45:89\u2013103.","journal-title":"Eur Heart J"},{"key":"3042_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","volume":"21","author":"S Toldo","year":"2024","unstructured":"Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2024;21:219\u201337.","journal-title":"Nat Rev Cardiol"},{"key":"3042_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41514-024-00170-4","volume":"10","author":"MOJ Grootaert","year":"2024","unstructured":"Grootaert MOJ. Cell senescence in cardiometabolic diseases. NPJ Aging. 2024;10:1\u201314.","journal-title":"NPJ Aging"},{"key":"3042_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jacbts.2023.12.003","volume":"9","author":"M Kumar","year":"2024","unstructured":"Kumar M, Yan P, Kuchel GA, Xu M. Cellular senescence as a targetable risk factor for cardiovascular diseases. JACC Basic Transl Sci. 2024;9:522\u201334.","journal-title":"JACC Basic Transl Sci"},{"key":"3042_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","volume":"8","author":"NH Adamstein","year":"2023","unstructured":"Adamstein NH, Cornel JH, Davidson M, Libby P, de Remigis A, Jensen C, et al. Association of interleukin 6 inhibition with Ziltivekimab and the neutrophil-lymphocyte ratio: a secondary analysis of the RESCUE clinical trial. JAMA Cardiol. 2023;8:177\u201381.","journal-title":"JAMA Cardiol"},{"key":"3042_CR13","doi-asserted-by":"publisher","first-page":"e986","DOI":"10.1016\/j.jacl.2024.08.005","volume":"18","author":"R Jiang","year":"2024","unstructured":"Jiang R, Ruan H, Wu W, Wang Y, Huang H, Lu X, et al. Monocyte\/lymphocyte ratio as a risk factor of cardiovascular and all-cause mortality in coronary artery disease with low-density lipoprotein cholesterol levels below 1.4 mmol\/L: a large longitudinal multicenter study. J Clin Lipidol. 2024;18:e986\u201394.","journal-title":"J Clin Lipidol"},{"key":"3042_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.07.019","author":"KS Rogacev","year":"2012","unstructured":"Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.019.","journal-title":"J Am Coll Cardiol"},{"key":"3042_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1161\/CIRCGENETICS.111.960385","volume":"5","author":"KE Berg","year":"2012","unstructured":"Berg KE, Ljungcrantz I, Andersson L, Bryngelsson C, Hedblad B, Fredrikson GN, et al. Elevated CD14++CD16\u2212 monocytes predict cardiovascular events. Circ Cardiovasc Genet. 2012;5:122\u201331.","journal-title":"Circ Cardiovasc Genet"},{"key":"3042_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41598-024-85041-4","volume":"15","author":"D-G Mo","year":"2025","unstructured":"Mo D-G, Liang M-T, Xu L, Li T, Han Q-F, Chen C, et al. The effect of NLRP3 inflammasome on cardiovascular prognosis in patients with acute coronary syndrome. Sci Rep. 2025;15:1187.","journal-title":"Sci Rep"},{"key":"3042_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12933-025-02777-7","volume":"24","author":"TT Yoo","year":"2025","unstructured":"Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium\u2013glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovasc Diabetol. 2025;24:227.","journal-title":"Cardiovasc Diabetol"},{"key":"3042_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"3042_CR19","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","volume":"128","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Rane M. Interleukin-6 signaling and anti-Interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128:1728\u201346.","journal-title":"Circ Res"},{"key":"3042_CR20","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505.","journal-title":"N Engl J Med"},{"key":"3042_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"3042_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"3042_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"3042_CR24","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","volume":"139","author":"RHM Furtado","year":"2019","unstructured":"Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation. 2019;139:2516\u201327.","journal-title":"Circulation"},{"key":"3042_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, Montecucco F, Carbone F, Camici GG, L\u00fcscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120:443\u201360.","journal-title":"Cardiovasc Res"},{"key":"3042_CR26","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146:1383\u2013405.","journal-title":"Circulation"},{"key":"3042_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf324","author":"T Baka","year":"2025","unstructured":"Baka T, Moore J, Qin F, Yurista SR, Zhang A, He H, et al. Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf324.","journal-title":"Eur Heart J"},{"key":"3042_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12933-025-02655-2","volume":"24","author":"W Wang","year":"2025","unstructured":"Wang W, Liu Y, Xu Q, Liu L, Zhu M, Li Y, et al. Cellular crosstalk in organotypic vasculature: mechanisms of diabetic cardiorenal complications and SGLT2i responses. Cardiovasc Diabetol. 2025;24:90.","journal-title":"Cardiovasc Diabetol"},{"key":"3042_CR29","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41467-025-55970-3","volume":"16","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Zhang M, Li C, Su L, Fu L, Wu S, et al. Endothelial AGGF1 promotes retinal angiogenesis by coordinating TNFSF12\/FN14 signalling. Nat Commun. 2025;16:1332.","journal-title":"Nat Commun"},{"key":"3042_CR30","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","volume":"43","author":"F Zannad","year":"2022","unstructured":"Zannad F, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Sumin M, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J. 2022;43:4991\u20135002.","journal-title":"Eur Heart J"},{"key":"3042_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf135","author":"MG Daskalaki","year":"2025","unstructured":"Daskalaki MG, Lapi I, Hurst AE, Al-Qahtani A, Vergadi E, Tsatsanis C. Epigenetic and metabolic regulation of macrophage responsiveness and memory. J Immunol. 2025. https:\/\/doi.org\/10.1093\/jimmun\/vkaf135.","journal-title":"J Immunol"},{"key":"3042_CR32","doi-asserted-by":"publisher","first-page":"e70059","DOI":"10.1111\/dme.70059","volume":"42","author":"MU Shah","year":"2025","unstructured":"Shah MU, Cliff CL, Squires PE, Lee K, Hills CE. The cardio-renal-metabolic role of the nod-like receptor protein-3 and senescence-associated secretory phenotype in early sodium\/glucose cotransporter-2 inhibitor therapy in people with diabetes who have had a myocardial infarction. Diabet Med. 2025;42:e70059.","journal-title":"Diabet Med"},{"key":"3042_CR33","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","volume":"138","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618\u201351.","journal-title":"Circulation"},{"key":"3042_CR34","doi-asserted-by":"crossref","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, ESC Scientific Document Group, Prescott E, Cosentino F, Abdelhamid M, Aboyans V, Antoniou S, Asteggiano R, Baumgartner I, Buccheri S, Bueno H, \u010celutkien\u0117 J, Chieffo A, Christersson C, Coats A, Cosyns B, Czerny M, Deaton C, Falk V, Ference BA, Filippatos G, Fisher M, Huikuri H, Ibanez B, Jaarsma T, James S, Khunti K, K\u00f8ber L, Koskinas KC, Lewis BS, L\u00f8chen M-L, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Parati G, Pasquet AA, Patrono C, Petersen SE, Piepoli MF, Rakisheva A, Rossello X, Rossing P, Ryd\u00e9n L, Standl E, Tokgozoglu L, Touyz RM, Visseren F, Volpe M, Vrints C, Witkowski A, Hazarapetyan L, Zirlik A, Rustamova Y, Van De Borne P, Sokolovi\u0107 \u0160, Gotcheva N, Milicic D, Agathangelou P, Vrabl\u00edk M, Schou M, Hasan-Ali H, Viigimaa M, Lautam\u00e4ki R, Aboyans V, Klimiashvili Z, Kelm M, Siasos G, Kiss RG, Libungan B, Durkan M, Zafrir B, Colivicchi F, Tundybayeva M, Byty\u00e7i I, Mirrakhimov E, Trusinskis K, Saad\u00e9 G, Badarien\u0117 J, Banu C-A, Magri CJ, Boskovic A, Hattaoui ME, Martens F, Bosevski M, Knudsen EC, Burchardt P, Fontes-Carvalho R, Vinereanu D, Mancini T, Beleslin B, Martinka E, Fras Z, Conde AC, Mellbin L, Carballo D, Bsata W, Mghaieth F, Gungor B, Mitchenko O, Wheatcroft S, Trigulova R, Prescott E, James S, Arbelo E, Baigent C, Borger MA, Buccheri S, Ibanez B, K\u00f8ber L, Koskinas KC, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet AA, Rakisheva A, Rocca B, Rossell\u00f3 X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043\u2013140.","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"3042_CR35","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/eurheartj\/ehp070","volume":"30","author":"S \u00d8rn","year":"2009","unstructured":"\u00d8rn S, Manhenke C, Ueland T, Dam\u00e5s JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J. 2009;30:1180\u20136.","journal-title":"Eur Heart J"},{"key":"3042_CR36","doi-asserted-by":"publisher","first-page":"26692","DOI":"10.1038\/s41598-024-76836-6","volume":"14","author":"X Li","year":"2024","unstructured":"Li X, Liu M, Wang G. The neutrophil\u2013lymphocyte ratio is associated with all-cause and cardiovascular mortality in cardiovascular patients. Sci Rep. 2024;14:26692.","journal-title":"Sci Rep"},{"key":"3042_CR37","first-page":"1826","volume":"20","author":"J Zhu","year":"2019","unstructured":"Zhu J, Wu S, Hu S, Li H, Li M, Geng X, et al. NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. Mol Med Rep. 2019;20:1826\u201336.","journal-title":"Mol Med Rep"},{"key":"3042_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/db12-0420","volume":"62","author":"H-M Lee","year":"2013","unstructured":"Lee H-M, Kim J-J, Kim HJ, Shong M, Ku BJ, Jo E-K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62:194\u2013204.","journal-title":"Diabetes"},{"key":"3042_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jjcc.2024.03.003","volume":"84","author":"M Khair","year":"2024","unstructured":"Khair M, Khair M, Vangaveti VN, Malabu UH. The role of the NLRP3 inflammasome in atherosclerotic disease: systematic review and meta-analysis. J Cardiol. 2024;84:14\u201321.","journal-title":"J Cardiol"},{"key":"3042_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jacbts.2021.08.006","volume":"7","author":"MB Olsen","year":"2021","unstructured":"Olsen MB, Gregersen I, Sandanger \u00d8, Yang K, Sokolova M, Halvorsen BE, et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl Sci. 2021;7:84\u201398.","journal-title":"JACC Basic Transl Sci"},{"key":"3042_CR41","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/eurheartj\/ehab107","volume":"42","author":"SJ Schunk","year":"2021","unstructured":"Schunk SJ, Kleber ME, M\u00e4rz W, Pang S, Zewinger S, Triem S, et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. 2021;42:1742\u201356.","journal-title":"Eur Heart J"},{"key":"3042_CR42","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jacc.2020.08.026","volume":"76","author":"J Silvain","year":"2020","unstructured":"Silvain J, Kerneis M, Zeitouni M, Lattuca B, Galier S, Brugier D, et al. Interleukin-1\u03b2 and risk of premature death in patients with myocardial infarction. J Am Coll Cardiol. 2020;76:1763\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"3042_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2018","unstructured":"Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018;15:203\u201314.","journal-title":"Nat Rev Cardiol"},{"key":"3042_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JP-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677\u201387.","journal-title":"Nat Med"},{"key":"3042_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-04786-w","volume":"13","author":"H Kong","year":"2022","unstructured":"Kong H, Zhao H, Chen T, Song Y, Cui Y. Targeted P2X7\/NLRP3 signaling pathway against inflammation, apoptosis, and pyroptosis of retinal endothelial cells in diabetic retinopathy. Cell Death Dis. 2022;13:1\u201313.","journal-title":"Cell Death Dis"},{"key":"3042_CR46","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.4049\/jimmunol.2200838","volume":"210","author":"F Wu","year":"2023","unstructured":"Wu F, Wei H, Hu Y, Gao J, Xu S. Upregulation of P2X7 exacerbates myocardial ischemia-reperfusion injury through enhancing inflammation and apoptosis in diabetic mice. J Immunol. 2023;210:1962\u201373.","journal-title":"J Immunol"},{"key":"3042_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5603\/CJ.a2020.0074","volume":"28","author":"X-X Shi","year":"2021","unstructured":"Shi X-X, Zheng K-C, Shan P-R, Zhang L, Wu S-J, Huang Z-Q. Elevated circulating level of P2X7 receptor is related to severity of coronary artery stenosis and prognosis of acute myocardial infarction. Cardiol J. 2021;28:453\u20139.","journal-title":"Cardiol J"},{"key":"3042_CR48","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1161\/01.CIR.101.18.2149","volume":"101","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of Tumor Necrosis Factor-\u03b1 and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149\u201353.","journal-title":"Circulation"},{"key":"3042_CR49","doi-asserted-by":"publisher","first-page":"ehad655.1383","DOI":"10.1093\/eurheartj\/ehad655.1383","volume":"44","author":"MA Matter","year":"2023","unstructured":"Matter MA, Wang YJ, Rossi VA, Heg D, Costantino S, Staehli BE, et al. Interleukin-6 plasma levels are elevated in patients with acute myocardial infarction and predict death or recurrent infarction within 1 year\u2014a case-control study. Eur Heart J. 2023;44:ehad655.1383.","journal-title":"Eur Heart J"},{"key":"3042_CR50","unstructured":"Novo Nordisk. ARTEMIS\u2014Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. clinicaltrials.gov; 2025. Available at https:\/\/clinicaltrials.gov\/study\/NCT06118281. Accessed 21 May 2025."},{"key":"3042_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ehjci\/jeae314","volume":"26","author":"ME Annink","year":"2025","unstructured":"Annink ME, Kraaijenhof JM, Beverloo CYY, Oostveen RF, Verberne HJ, Stroes ESG, et al. Estimating inflammatory risk in atherosclerotic cardiovascular disease: Plaque over plasma? Eur Heart J Cardiovasc Imaging. 2025;26:444\u201360.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"3042_CR52","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.1038\/s41598-025-89125-7","volume":"15","author":"H Li","year":"2025","unstructured":"Li H, Zhu Q, Wang W, Bao Y, Bai Y, Liu H, et al. Identification of biomarkers associated with M1 macrophages in the ST-segment elevation myocardial infarction through bioinformatics and machine learning approaches. Sci Rep. 2025;15:11069.","journal-title":"Sci Rep"},{"key":"3042_CR53","first-page":"941","volume":"33","author":"S Fitzsimons","year":"2023","unstructured":"Fitzsimons S, Mu\u00f1oz-San Mart\u00edn M, Nally F, Dillon E, Fashina IA, Strowitzki MJ, et al. Inhibition of pro-inflammatory signaling in human primary macrophages by enhancing arginase-2 via target site blockers. Mol Ther. 2023;33:941\u201359.","journal-title":"Mol Ther"},{"key":"3042_CR54","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.bbrc.2006.03.197","volume":"344","author":"S Mine","year":"2006","unstructured":"Mine S, Okada Y, Tanikawa T, Kawahara C, Tabata T, Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun. 2006;344:780\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"3042_CR55","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1161\/01.CIR.0000131160.94926.6E","volume":"109","author":"KH Han","year":"2004","unstructured":"Han KH, Hong K-H, Park J-H, Ko J, Kang D-H, Choi K-J, et al. C-reactive protein promotes monocyte chemoattractant protein-1\u2013mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation. 2004;109:2566\u201371.","journal-title":"Circulation"},{"key":"3042_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamacardio.2020.5392","volume":"6","author":"MK Georgakis","year":"2021","unstructured":"Georgakis MK, de Lemos JA, Ayers C, Wang B, Bj\u00f6rkbacka H, Pana TA, et al. Association of circulating monocyte chemoattractant protein\u20131 levels with cardiovascular mortality: a meta-analysis of population-based studies. JAMA Cardiol. 2021;6:587\u201392.","journal-title":"JAMA Cardiol"},{"key":"3042_CR57","doi-asserted-by":"publisher","first-page":"e035820","DOI":"10.1161\/JAHA.124.035820","volume":"13","author":"Q Xu","year":"2024","unstructured":"Xu Q, Liu Y, Tian X, Xia X, Zhang Y, Zhang X, et al. Monocyte chemoattractant protein\u20101, inflammatory biomarkers, and prognosis of patients with ischemic stroke or transient ischemic attack: fndings from a nationwide registry study. J Am Heart Assoc. 2024;13:e035820.","journal-title":"J Am Heart Assoc"},{"key":"3042_CR58","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/CIRCRESAHA.119.315380","volume":"125","author":"MK Georgakis","year":"2019","unstructured":"Georgakis MK, Malik R, Bj\u00f6rkbacka H, Pana TA, Demissie S, Ayers C, et al. Circulating monocyte chemoattractant protein-1 and risk of stroke: meta-analysis of population-based studies involving 17\u2009180 individuals. Circ Res. 2019;125:773\u201382.","journal-title":"Circ Res"},{"issue":"24","key":"3042_CR59","first-page":"00469","volume":"S1742\u20137061","author":"J Wen","year":"2024","unstructured":"Wen J, Guan Y, Niu H, Dang Y, Guan J. Targeting cardiac resident CCR2+ macrophage-secreted MCP-1 to attenuate inflammation after myocardial infarction. Acta Biomater. 2024;S1742\u20137061(24):00469.","journal-title":"Acta Biomater"},{"key":"3042_CR60","doi-asserted-by":"publisher","first-page":"111594","DOI":"10.1016\/j.isci.2024.111594","volume":"28","author":"H Ding","year":"2025","unstructured":"Ding H, Zhang Q, Yang R, Fu L, Jiang H, Zhu Q, et al. Aberrant STING activation promotes macrophage senescence by suppressing autophagy in vascular aging from diabetes. iScience. 2025;28:111594.","journal-title":"iScience"},{"key":"3042_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yjmcc.2024.08.001","volume":"195","author":"P Zhai","year":"2024","unstructured":"Zhai P, Sung E-A, Shiheido-Watanabe Y, Takayama K, Tian Y, Sadoshima J. Suppression of autophagy induces senescence in the heart. J Mol Cell Cardiol. 2024;195:83\u201396.","journal-title":"J Mol Cell Cardiol"},{"key":"3042_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41420-023-01792-5","volume":"10","author":"Y Luan","year":"2024","unstructured":"Luan Y, Zhu X, Jiao Y, Liu H, Huang Z, Pei J, et al. Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets. Cell Death Discov. 2024;10:78.","journal-title":"Cell Death Discov"},{"key":"3042_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01840-1","volume":"9","author":"R Chen","year":"2024","unstructured":"Chen R, Zhang H, Tang B, Luo Y, Yang Y, Zhong X, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Sig Transduct Target Ther. 2024;9:1\u201344.","journal-title":"Sig Transduct Target Ther"},{"key":"3042_CR64","doi-asserted-by":"publisher","first-page":"11996","DOI":"10.1038\/s41598-025-92328-7","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zheng Y, Liang X, Chang Y, Liu Y, Cheng X, et al. \u03b1-lipoic acid alleviate myocardial infarction by suppressing age-independent macrophage senescence. Sci Rep. 2025;15:11996.","journal-title":"Sci Rep"},{"key":"3042_CR65","doi-asserted-by":"publisher","first-page":"ehad655.1384","DOI":"10.1093\/eurheartj\/ehad655.1384","volume":"44","author":"Y Wang","year":"2023","unstructured":"Wang Y, Matter MA, Rossi VA, Heg D, Costantino S, Staehli BE, et al. In patients with acute myocardial infarction interleukin-8 levels are related to impaired renal function and predict recurrent infarction or death at 1-year follow-up\u2014a case-control study. Eur Heart J. 2023;44:ehad655.1384.","journal-title":"Eur Heart J"},{"key":"3042_CR66","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1016\/j.acvd.2024.05.039","volume":"117","author":"F Moulin","year":"2024","unstructured":"Moulin F, Brun C, Leboube S, Hayek A, Paccalet A, Azar L, et al. Osteopontin is a relevant prognostic biomarker in STEMI patients. Arch Cardiovasc Dis. 2024;117:S180.","journal-title":"Arch Cardiovasc Dis"},{"key":"3042_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.121.056019","volume":"145","author":"G Sreejit","year":"2022","unstructured":"Sreejit G, Nooti SK, Jaggers RM, Athmanathan B, Ho Park K, Al-Sharea A, et al. Retention of the NLRP3 inflammasome-primed neutrophils in the bone marrow is essential for myocardial infarction-induced granulopoiesis. Circulation. 2022;145:31\u201344.","journal-title":"Circulation"},{"key":"3042_CR68","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:2060\u20139.","journal-title":"Lancet"},{"key":"3042_CR69","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/01.CIR.0000155614.35441.69","volume":"111","author":"M Valgimigli","year":"2005","unstructured":"Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor Necrosis Factor-\u03b1 Receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation. 2005;111:863\u201370.","journal-title":"Circulation"},{"key":"3042_CR70","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/0002-8703(93)90526-F","volume":"126","author":"Y Miyao","year":"1993","unstructured":"Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 1993;126:1299\u2013304.","journal-title":"Am Heart J"},{"key":"3042_CR71","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1161\/01.CIR.102.18.2180","volume":"102","author":"PR Moreno","year":"2000","unstructured":"Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180\u20134.","journal-title":"Circulation"},{"key":"3042_CR72","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee S-G, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11:2127.","journal-title":"Nat Commun"},{"key":"3042_CR73","doi-asserted-by":"publisher","first-page":"565924","DOI":"10.3389\/fimmu.2020.565924","volume":"11","author":"A Gritsenko","year":"2020","unstructured":"Gritsenko A, Yu S, Martin-Sanchez F, Diaz-Del-Olmo I, Nichols E-M, Davis DM, et al. Priming is dispensable for NLRP3 inflammasome activation in human monocytes in vitro. Front Immunol. 2020;11:565924.","journal-title":"Front Immunol"},{"key":"3042_CR74","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"3042_CR75","doi-asserted-by":"publisher","first-page":"599511","DOI":"10.3389\/fimmu.2020.599511","volume":"11","author":"MJM Silvis","year":"2020","unstructured":"Silvis MJM, Kaffka Genaamd Dengler SE, Odille CA, Mishra M, van der Kaaij NP, Doevendans PA, et al. Damage-associated molecular patterns in myocardial infarction and heart transplantation: the road to translational success. Front Immunol. 2020;11:599511.","journal-title":"Front Immunol"},{"key":"3042_CR76","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","volume":"22","author":"K Huang","year":"2023","unstructured":"Huang K, Luo X, Liao B, Li G, Feng J. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc Diabetol. 2023;22:86.","journal-title":"Cardiovasc Diabetol"},{"key":"3042_CR77","doi-asserted-by":"publisher","first-page":"e167700","DOI":"10.1172\/JCI167700","volume":"133","author":"KR Tuttle","year":"2023","unstructured":"Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. J Clin Invest. 2023;133:e167700.","journal-title":"J Clin Invest"},{"key":"3042_CR78","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41419-022-05089-w","volume":"13","author":"M Varela-Eir\u00edn","year":"2022","unstructured":"Varela-Eir\u00edn M, Carpintero-Fern\u00e1ndez P, Guiti\u00e1n-Caama\u00f1o A, Varela-V\u00e1zquez A, Garc\u00eda-Yuste A, S\u00e1nchez-Temprano A, et al. Extracellular vesicles enriched in connexin 43 promote a senescent phenotype in bone and synovial cells contributing to osteoarthritis progression. Cell Death Dis. 2022;13:681.","journal-title":"Cell Death Dis"},{"key":"3042_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-021-00797-2","volume":"7","author":"R Liu","year":"2021","unstructured":"Liu R, Cui J, Sun Y, Xu W, Wang Z, Wu M, et al. Autophagy deficiency promotes M1 macrophage polarization to exacerbate acute liver injury via ATG5 repression during aging. Cell Death Discov. 2021;7:1\u201314.","journal-title":"Cell Death Discov"},{"key":"3042_CR80","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.177557","author":"D Zhao","year":"2024","unstructured":"Zhao D, Tu C, Zhang L, Guda T, Gu S, Jiang JX. Activation of connexin hemichannels enhances mechanosensitivity and anabolism in disused and aged bone. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.177557.","journal-title":"JCI Insight."},{"key":"3042_CR81","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11883-024-01229-z","volume":"26","author":"J Wang","year":"2024","unstructured":"Wang J, Wu Q, Wang X, Liu H, Chen M, Xu L, et al. Targeting macrophage phenotypes and metabolism as novel therapeutic approaches in atherosclerosis and related cardiovascular diseases. Curr Atheroscler Rep. 2024;26:573\u201388.","journal-title":"Curr Atheroscler Rep"},{"key":"3042_CR82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacbts.2024.01.019","volume":"9","author":"A Paccalet","year":"2024","unstructured":"Paccalet A, Badawi S, Pillot B, Augeul L, Mechtouff L, Harhous Z, et al. Deleterious anti-inflammatory macrophage recruitment in early\u00a0post-infarction phase: unraveling the IL-6\/MCP-1\/STAT3 axis. JACC Basic Transl Sci. 2024;9:593\u2013604.","journal-title":"JACC Basic Transl Sci"},{"key":"3042_CR83","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nbt.1989","volume":"29","author":"F Leuschner","year":"2011","unstructured":"Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29:1005\u201310.","journal-title":"Nat Biotechnol"},{"key":"3042_CR84","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1161\/ATVBAHA.122.317492","volume":"42","author":"L \u017divkovi\u0107","year":"2022","unstructured":"\u017divkovi\u0107 L, Asare Y, Bernhagen J, Dichgans M, Georgakis MK. Pharmacological targeting of the CCL2\/CCR2 axis for atheroprotection: a meta-analysis of preclinical studies. Arterioscler Thromb Vasc Biol. 2022;42:e131\u201344.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3042_CR85","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.3390\/ijms21218189","volume":"21","author":"M Pirklbauer","year":"2020","unstructured":"Pirklbauer M, Bernd M, Fuchs L, Staudinger P, Corazza U, Leierer J, et al. Empagliflozin inhibits basal and IL-1\u03b2-mediated MCP-1\/CCL2 and endothelin-1 expression in human proximal tubular cells. Int J Mol Sci. 2020;21:8189.","journal-title":"Int J Mol Sci"},{"key":"3042_CR86","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","volume":"60","author":"JH Han","year":"2017","unstructured":"Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE\u2212\/\u2212 mice fed a western diet. Diabetologia. 2017;60:364\u201376.","journal-title":"Diabetologia"},{"key":"3042_CR87","doi-asserted-by":"publisher","first-page":"e000783","DOI":"10.1136\/bmjdrc-2019-000783","volume":"7","author":"L Xu","year":"2019","unstructured":"Xu L, Nagata N, Chen G, Nagashimada M, Zhuge F, Ni Y, et al. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diabetes Res Care. 2019;7:e000783.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3042_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139576","author":"M DeBerge","year":"2021","unstructured":"DeBerge M, Glinton K, Subramanian M, Wilsbacher LD, Rothlin CV, Tabas I, et al. Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI139576.","journal-title":"J Clin Invest"},{"key":"3042_CR89","unstructured":"Zhang Z, He X, Sun Y, Li J, Sun J. Type 2 diabetes mellitus: a metabolic model of accelerated aging\u2014multi-organ mechanisms and intervention approaches. Aging Dis. 2025."},{"key":"3042_CR90","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00125-019-4934-x","volume":"62","author":"AK Palmer","year":"2019","unstructured":"Palmer AK, Gustafson B, Kirkland JL, Smith U. Cellular senescence: at the nexus between ageing and diabetes. Diabetologia. 2019;62:1835\u201341.","journal-title":"Diabetologia"},{"key":"3042_CR91","doi-asserted-by":"publisher","first-page":"e15408","DOI":"10.1111\/dme.15408","volume":"42","author":"PCA Phillips","year":"2025","unstructured":"Phillips PCA, de Sousa Loreto Aresta Branco M, Cliff CL, Ward JK, Squires PE, Hills CE. Targeting senescence to prevent diabetic kidney disease: exploring molecular mechanisms and potential therapeutic targets for disease management. Diabet Med. 2025;42:e15408.","journal-title":"Diabet Med"},{"key":"3042_CR92","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cvr\/cvaf030","volume":"121","author":"SD Stojanovi\u0107","year":"2025","unstructured":"Stojanovi\u0107 SD, Thum T, Bauersachs J. Anti-senescence therapies: a new concept to address cardiovascular disease. Cardiovasc Res. 2025;121:730\u201347.","journal-title":"Cardiovasc Res"},{"key":"3042_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41514-025-00227-y","volume":"11","author":"ZE Yesilyurt-Dirican","year":"2025","unstructured":"Yesilyurt-Dirican ZE, Qi C, Wang Y-C, Simm A, Deelen L, Hafiz Abbas Gasim A, et al. SGLT2 inhibitors as a novel senotherapeutic approach. NPJ Aging. 2025;11:1\u201315.","journal-title":"NPJ Aging"},{"key":"3042_CR94","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.yjmcc.2016.10.005","volume":"100","author":"RP Iyer","year":"2016","unstructured":"Iyer RP, de Castro Br\u00e1s LE, Patterson NL, Bhowmick M, Flynn ER, Asher M, et al. Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution. J Mol Cell Cardiol. 2016;100:109\u201317.","journal-title":"J Mol Cell Cardiol"},{"key":"3042_CR95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nri3399","volume":"13","author":"E Kolaczkowska","year":"2013","unstructured":"Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159\u201375.","journal-title":"Nat Rev Immunol"},{"key":"3042_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-020-00840-w","volume":"116","author":"C Baumeier","year":"2021","unstructured":"Baumeier C, Escher F, Aleshcheva G, Pietsch H, Schultheiss H-P. Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy. Basic Res Cardiol. 2021;116:1.","journal-title":"Basic Res Cardiol"},{"key":"3042_CR97","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.3390\/cells12222647","volume":"12","author":"MG Filipovic","year":"2023","unstructured":"Filipovic MG, Luedi MM. Cardiovascular biomarkers: current status and future directions. Cells. 2023;12:2647.","journal-title":"Cells"},{"key":"3042_CR98","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14796678.2025.2477947","volume":"21","author":"V Rai","year":"2025","unstructured":"Rai V. Current and future role of biomarkers in the monitoring and prognosis of coronary artery disease. Future Cardiol. 2025;21:331\u20133.","journal-title":"Future Cardiol"},{"key":"3042_CR99","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s43587-024-00642-y","volume":"4","author":"G Katsuumi","year":"2024","unstructured":"Katsuumi G, Shimizu I, Suda M, Yoshida Y, Furihata T, Joki Y, et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nat Aging. 2024;4:926\u201338.","journal-title":"Nat Aging"},{"key":"3042_CR100","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/eji.200838683","volume":"39","author":"JC Scatizzi","year":"2009","unstructured":"Scatizzi JC, Mavers M, Hutcheson J, Young B, Shi B, Pope RM, et al. The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages. Eur J Immunol. 2009;39:820\u20135.","journal-title":"Eur J Immunol"},{"key":"3042_CR101","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2025.2469315","author":"Q Tang","year":"2025","unstructured":"Tang Q, Tang K, Markby GR, Parys M, Phadwal K, MacRae VE, et al. Autophagy regulates cellular senescence by mediating the degradation of CDKN1A\/p21 and CDKN2A\/p16 through SQSTM1\/p62-mediated selective autophagy in myxomatous mitral valve degeneration. Autophagy. 2025. https:\/\/doi.org\/10.1080\/15548627.2025.2469315.","journal-title":"Autophagy"},{"key":"3042_CR102","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1161\/01.CIR.0000148681.01282.89","volume":"110","author":"AJ Merched","year":"2004","unstructured":"Merched AJ, Chan L. Absence of p21Waf1\/Cip1\/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation. 2004;110:3830\u201341.","journal-title":"Circulation"},{"key":"3042_CR103","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12933-023-01754-2","volume":"22","author":"L Scisciola","year":"2023","unstructured":"Scisciola L, Taktaz F, Fontanella RA, Pesapane A, Surina, Cataldo V, et al. Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors. Cardiovasc Diabetol. 2023;22:24.","journal-title":"Cardiovasc Diabetol."},{"key":"3042_CR104","doi-asserted-by":"crossref","unstructured":"Cao J, Roth S, Zhang S, Kopczak A, Mami S, Asare Y, Georgakis MK, Messerer D, Horn A, Shemer R, Jacqmarcq C, Picot A, Green JP, Schlegl C, Li X, Tomas L, Dutsch A, Liman TG, Endres M, Wernsdorf SR, F\u00fcrle C, Carofiglio O, Zhu J, Brough D, DEMDAS Study Group, Dichgans M, Endres M, Georgakis MK, Liman TG, Petzold G, Spottke A, Wunderlich S, Zerr I, Hornung V, Dichgans M, Vivien D, Schulz C, Dor Y, Tiedt S, Sager HB, Grosse GM, Liesz A. DNA-sensing inflammasomes cause recurrent atherosclerotic stroke. Nature. 2024;633:433\u201341.","DOI":"10.1038\/s41586-024-07803-4"},{"key":"3042_CR105","first-page":"A8","volume":"111","author":"C Costello","year":"2025","unstructured":"Costello C, Chemaly M, McDaid-McCloskey S-L, Coyle S, Peace A, Aj B, et al. P12 NLRP3 inflammasome-associated proteins as predictors of recurrent cardiac events. Heart. 2025;111:A8\u20139.","journal-title":"Heart"},{"key":"3042_CR106","first-page":"A14205","volume":"128","author":"J Hoffmann","year":"2013","unstructured":"Hoffmann J, Pyttel L, Thiele P, Troidl C, Liebetrau C, Szardien S, et al. Abstract 14205: myocardial injury induces AIM2 inflammasome expression in neutrophil granulocytes in patients with acute myocardial infarction. Circulation. 2013;128:A14205\u2013A14205.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03042-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:06:40Z","timestamp":1770887200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03042-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03042-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and subsequent amendments were approved by the East of Scotland Research Ethics Service Research Ethics Committee (22\/ES\/0047), and the Health Research Authority (integrated research application system (IRAS:319343). This study was adopted by the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) central portfolio management system (CPMS:54499). Participants were given prior written information with regards to the study. All participants provided written informed consent prior to enrolment and randomisation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}